Universal solid tumor therapy with CD5-deleted, DSG2-directed CAR-T cells. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.
A growing body of evidence indicates that studies utilizing organoids and microtissues yield more predictive and translational insights compared to traditional two-dimensional (2D) monolayer cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results